PsiOxus aims to be the world’s leading company in tumour re-programming, delivering medicines of value to patients with cancer.
PsiOxus is a clinical stage oncology company pioneering systemic immune oncology products that drive sustained reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy.
Our validated T-SIGn® vector platform can deliver multiple transgene payloads that re-program both primary and metastatic tumors. We have a rapidly expanding pipeline of novel monotherapy and combination products to dramatically improve outcomes for patients with cancer.
Find our more about us at www.psioxus.com
Location: United Kingdom, England, Vale of White Horse
Employees: 51-200
Total raised: $75.6M
Founded date: 2010
Investors 2
| Date | Name | Website |
| 26.03.2022 | ARCH Ventu... | archventur... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 19.05.2015 | Series C | $38.78M | - |
| 22.11.2012 | - | $2.71M | - |
| 09.07.2012 | Series B | $34.11M | - |
Mentions in press and media 10
| Date | Title | Description | Source |
| 05.01.2023 | Akamis Bio Announces $30 Million Financing, Provides Clinica... | $30 million convertible note financing co-led by ARCH Venture Partners, Parker Institute for Can... | ipgroupplc... |
| 20.12.2016 | Bristol-Myers Squibb signs exclusive worldwide license agree... | Bristol-Myers Squibb Company and PsiOxus Therapeutics today announced an agreement granting Bristol-... | mercia.co.... |
| 19.05.2015 | PsiOxus Therapeutics Closes £25M Series C Financing | PsiOxus Therapeutics Ltd., an Oxford, UK-based oncolytic immuno-oncology company, closed a £25m Seri... | finsmes.co... |
| 19.05.2015 | Mercia participates in PsiOxus funding round | Mercia Technologies PLC (AIM: MERC, “Mercia”), a Midlands based leader in the funding and commercial... | mercia.co.... |
| 16.04.2015 | PsiOxus Therapeutics expands clinical studies for immuno-onc... | PsiOxus Therapeutics Ltd. (PsiOxus), an Oxford, UKbased biotechnology company developing innovative ... | mercia.co.... |
| 16.04.2015 | PsiOxus Therapeutics to present promising new data on novel ... | PsiOxus Therapeutics Ltd. (PsiOxus), an oncolytic immunoncology company, has announced that it will ... | mercia.co.... |
| 22.11.2012 | PsiOxus Receives £1.7M from Biomedical Catalyst | PsiOxus, an Oxford, UK-based development stage biotechnology company developing novel therapeutics f... | finsmes.co... |
| 09.07.2012 | PsiOxus Therapeutics Closes £22M Series B Equity Financing | PsiOxus Therapeutics, Ltd., an Oxford, UK-based development stage biotechnology company using non-tr... | finsmes.co... |
| 09.07.2012 | PsiOxus Therapeutics Inks $34M in Series B | LONDON, ENGLAND, PsiOxus Therapeutics announced that it has closed a Series B round of equity fina... | vcnewsdail... |
| - | Psioxus Therapeutics | “At PsiOxus Therapeutics, we are committed to unlocking the potential of immuno-oncology in solid tu... | fastfounde... |